Basic Company Data Data as of: January 31, 2011 Current Price $83.

99
Symbol ALXN ALEXION PHARMACEUTICALS INC H&C Composite Score
Description Alexion Pharmaceuticals, Inc., a biopharmaceutical company, researches and
Strong Buy
develops proprietary immunoregulatory compounds for the treatment of autoimmune
and cardiovascular diseases. The Company develops C5 complement inhibitors and
Apogens which are two classes of potential therapeutic compounds designed to
9.2
selectively target specific disease-causing segments of the immune system.

Sector Health Care

Industry Pharmaceuticals, Biotechnology 0 1 2 3 4 5
Last Report Date 10/21/2010 Technical Score Fundamental Score
Earnings Date 2/10/2011 IPO Date 2/27/1996
Fundamentals Technicals
Market Cap. $7.6 B BETA 0.77 Price $83.99 MACD Overbought
Price/Earnings 83.99 1Yr. EPS Growth Rate % 125.58% 50-Day MA $80.13 Stochastics Trend Down
Forward Price/Earnings 36.93 5Yr. Avg. EPS Growth Rate % #N/A N/A 200-Day MA $63.44 RSI Signal Trend Down
Price/Book 9.40 EPS Growth QoQ 30.43% 50/200 Day MA $16.69 S/T Trend Up
Forward PEG Ratio 1.14 Revenue Growth QoQ 27.94% Volume Pressure 1.68 L/T Trend Up
Return on Equity #N/A N/A Dividend Yield 0.00% Average Daily Volume 595,363 Bull / Bear Bull Trend
LT Debt/Equity 1.51% Cash Flow Per Share 1.33 M-Score (0 - 100%) 94%
H&C Fundamental Score 4.6 H&C Technical Score 4.6
Ownership Data
Inst. Buy/Sell Ratio 2.09 Management Ownership 1.71% 50 Day Moving Average S/T Support L/T Support
% Change of Insider Holdings 1.79% Short Interest Ratio 9.37 20 Day Moving Average S/T Resistance L/T Resistance

ALEXION PHARMACEUTICALS INC $88

$86
$84
$82
$80
$78
$76
$74
$72
$70
$68
$66
$64
$62
$60

10.0
Bull Trend Bear Trend

5.0

0.0
3.0
Up / Down Volume Ratio 2.5
2.0
1.5
1.0
0.5
0.0
60

40

20

0
6-Oct-10 20-Oct-10 3-Nov-10 17-Nov-10 2-Dec-10 16-Dec-10 31-Dec-10 14-Jan-11 31-Jan-11
Volume x100,000
Fundamentals
ALEXION PHARMACEUTICALS INC
1
Earnings Per Share 2
Reported Estimate Target Price 19 Reported Estimate
$0.70 $100
$0.60 $90
$0.50 $80
$0.40 $70
$0.30 $60
$0.20 $50

$0.10 $40

$0.00 $30

-$0.10 $20

-$0.20 $10

-$0.30 $0

Total Revenues 1
Reported Estimate
Ownership EPS & Revenue Growth
Investment Advisor 84.31% Quarter EPS Growth Rev. Growth
$250
Hedge Fund Manager 8.68% FQ4 2008 3% # 129%
Pension Fund (ERISA) 2.29% FQ1 2009 191% # 78%
Individual 1.63% FQ2 2009 667% 55%
$200
Mutual Fund Manager 1.43% FQ3 2009 26% 34%
Insurance Company 1.00% FQ4 2009 35% 43%
$150
Corporation 0.38% FQ1 2010 44% 45%
Bank 0.17% FQ2 2010 4% 36%
FQ3 2010 3% 38%
$100 Top Holders and % Outstanding Forward Growth Estimates
FIDELITY MANAGEMENT 14.93% Quarter EPS Growth Rev. Growth
T ROWE PRICE ASSOCIA 6.76% FQ4 2010 117% 39%
$50
COLUMBIA WANGER ASSE 4.74% FQ1 2011 133% 39%
VANGUARD GROUP INC 3.64% FQ2 2011 134% 38%
WELLS CAPITAL MANAGE 3.41% FQ3 2011 96% 30%
$0
JP MORGAN CHASE & CO 3.16%
TURNER INVESTMENT PA 3.00%
WESTFIELD CAPITAL MG 2.63%

Largest Geographic Segmentation of Revenue Product Segmentation of Revenue

Yearly Yearly
Segment Name FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 Segment Name FY 2009 FY 2008 FY 2007 FY 2006 FY 2005
Outside U.S. 226.97 145.80 20.19 #N/A N/A #N/A N/A Soliris $386.80 $259.00 $66.38 #N/A N/A #N/A N/A
United States 159.83 113.20 51.86 1.56 1.06 Contract Research Revenue #N/A N/A $0.10 $5.66 $1.56 $1.06
Worldwide (Contract Research) #N/A N/A 0.10 5.66 #N/A N/A #N/A N/A

Disclosure: This material is provided for information only and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. This material is not a complete analysis of all material facts respecting any issuer, industry or
security or of your investment objectives, parameters, needs or financial situation, and therefore is not a sufficient basis alone on which to base an investment decision. Horowitz & Company clients may hold positions (long or short) in investments discussed. Please click for detailed
disclosures and additional information about our stock ratings and scoring.

1/31/2011